It has been reported that by combining HSPB1 silencing and BRAF inhibition melanoma cells are fully committed to death55 and, accordingly, reduced level of HSPB1 correlates with a less aggressive phenotype and improved survival in patients with melanoma56. This evidence concerns the gene BRAF and melanoma.